Anti-VEGF Therapeutics Market to Surpass US$ 13.1 Billion by 2032, Driven by Rising Prevalence of Retinal Disorders

Market Overview: A Growing Demand in Vision and Cancer Therapy

The Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Therapeutics Market is witnessing a slow yet steady rise in global demand, especially driven by the rising prevalence of chronic eye conditions and cancer. According to newly released industry data by Persistence Market Research, the market reached a valuation of US$ 12 billion in 2022 and is projected to grow to US$ 13.1 billion by 2032, expanding at a modest CAGR of 0.9%. Although growth appears restrained compared to other therapeutic classes, the expanding geriatric population and increasing cases of Age-related Macular Degeneration (AMD), diabetic retinopathy, and certain cancers make this a persistently relevant therapeutic area.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/33243

The Eylea segment leads the market in terms of product type due to its efficacy and long-term results in AMD and other retinal disorders. North America dominates geographically, claiming over 40% of global revenue in 2021. This dominance stems from robust healthcare infrastructure, early regulatory approvals, and an aging population susceptible to degenerative vision disorders. The U.S. particularly benefits from the presence of major pharmaceutical players and continued innovation in targeted biologics.

✦ Key Highlights from the Report

✦ The global Anti-VEGF therapeutics market is projected to reach US$ 13.1 billion by 2032.
✦ Eylea remains the highest revenue-generating product in the segment.
✦ North America holds more than 40% of the global market share.
✦ Age-related macular degeneration is a key driver in Anti-VEGF demand.
✦ Japan is projected to grow at the fastest CAGR of 1.2% through 2032.
✦ Diabetic Macular Edema (DME) therapies show strong adoption among diabetic patients.

Market Segmentation: Therapeutic Innovations Across Categories

The Anti-VEGF Therapeutics Market is segmented primarily by product type, disease indication, and end-user.

By Product Type, leading therapies include Eylea (aflibercept), Lucentis (ranibizumab), and Bevacizumab. Eylea, developed by Regeneron and Bayer, dominates due to its extended duration of action, reducing the frequency of injections needed. Bevacizumab, though used off-label in many cases, remains widely used due to its affordability.

By Indication, Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), and various cancers are major segments. Among these, AMD accounts for a substantial portion of prescriptions, followed by DME, as both are highly prevalent in elderly and diabetic populations.

By End User, hospitals, specialty clinics, and ambulatory surgical centers lead the segment. Specialty ophthalmology clinics, in particular, have shown increased adoption of intravitreal Anti-VEGF therapies due to technological advancements in delivery and monitoring.

Regional Insights: Market Dynamics by Geography

In North America, the market thrives on the back of rising incidence rates of eye disorders, favorable reimbursement frameworks, and a high geriatric population. U.S. remains the largest market, valued at US$ 4.6 billion by 2032, thanks to its technological leadership and the presence of dominant market players like Genentech and Regeneron.
Europe, led by the UK and Germany, also demonstrates stable growth. The UK market is set to reach US$ 527 million by 2032, reflecting both public health initiatives in early eye disease detection and pharmaceutical advances.
Asia-Pacific, notably Japan, is emerging as a fast-growing market, forecasted to grow at 1.2% CAGR. Japan's aging society and advancements in ophthalmic imaging and therapy drive strong demand. Moreover, increased healthcare spending and government focus on age-related disease management fuel expansion.
Other developing regions such as Latin America and Middle East & Africa present untapped potential but face constraints like lower diagnosis rates and limited patient access to biologics.

Market Drivers

The primary driver for market growth is the global rise in aging populations, as age is a significant risk factor for AMD, DR, and DME. Additionally, the escalating incidence of diabetes worldwide has increased demand for DME treatment using Anti-VEGF therapies. The growing burden of cancers-especially ovarian, cervical, and endometrial-where VEGF expression is high, has boosted the need for targeted therapies. Increasing investments in biopharmaceutical R&D, coupled with technological advancements in drug delivery systems, such as pre-filled syringes and long-acting injectables, further support market expansion.

Market Restraints

Despite therapeutic advances, the market faces notable restraints. High treatment costs, particularly for patented biologics, limit accessibility in lower-income nations. Moreover, angiogenesis is not the sole pathway for tumor growth, which means anti-VEGF therapy alone may not offer curative solutions, especially in cancers. The invasive nature of intravitreal injections and the risk of ocular complications, such as intraocular inflammation or endophthalmitis, remain significant barriers. Low diagnosis and screening rates in developing economies also curb broader treatment adoption.

Market Opportunities

Significant market opportunities lie in emerging economies where diagnostic infrastructure is rapidly improving. As healthcare access broadens and awareness rises, Anti-VEGF therapies can penetrate untapped regions. There's also a growing opportunity in biosimilar development, offering more cost-effective options to meet rising demand. Combination therapies, integrating anti-VEGF agents with anti-inflammatory or anti-fibrotic drugs, represent an avenue for improved patient outcomes. Additionally, personalized medicine and AI-driven diagnostics are paving the way for more accurate treatment strategies and earlier intervention.

Reasons to Buy the Report

✔ Gain insights into a market expected to reach US$ 13.1 billion by 2032.
✔ Understand emerging trends and technology innovations in biologic therapies.
✔ Identify strategic growth opportunities in high-potential regions like Japan and North America.
✔ Access competitive analysis and recent developments from key industry players.
✔ Analyze market segmentation to inform product strategy and portfolio diversification.

Company Insights

• F. Hoffmann-La Roche Ltd.
• Biogen
• Pfizer Inc
• Coherus BioSciences
• Amgen Inc
• Regeneron Pharmaceuticals Inc.
• Bayer AG
• Novartis AG

Recent Developments:

In April 2020, Bayer AG launched Eylea prefilled syringes across Europe, enhancing user convenience and dose accuracy across all 27 EU member states.
Regeneron Pharmaceuticals has been conducting Phase III trials of high-dose aflibercept, aiming to improve durability and reduce injection frequency, a major concern among patients.

Conclusion

The Anti-Vascular Endothelial Growth Factor Therapeutics Market is set for steady growth, underpinned by the rising global burden of degenerative vision disorders and cancers with vascular involvement. While the market faces headwinds such as high costs and complex treatment regimens, opportunities abound in biosimilars, combination therapies, and expansion into emerging markets. As aging populations continue to swell and healthcare systems adapt to new challenges, the role of Anti-VEGF therapies will become increasingly pivotal-not only in maintaining vision but in improving the quality of life for millions worldwide. With companies like Regeneron, Bayer, and Novartis pushing the boundaries of therapeutic innovation, the future of Anti-VEGF therapy appears promising and full of potential.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.